41 filings
Page 2 of 3
8-K
p5p3z mpycuy
7 Aug 19
Constellation Pharmaceuticals Announces Second-Quarter andSix-Month 2019 Financial Results
4:11pm
8-K
zj94o7laxr z161caxn
19 Jun 19
Entry into a Material Definitive Agreement
4:12pm
8-K
mmluw1joi23e5lsqk
10 Jun 19
Submission of Matters to a Vote of Security Holders
4:35pm
8-K
4k2ltayeken 66tt4
16 May 19
Constellation Pharmaceuticals Provides Interim Update of Data forCPI-0610 in ASCO and EHA Abstracts
9:01am
8-K
k4e2ll4 5apnw
15 May 19
2019 ASCO Annual Meeting
5:01pm
8-K
ag6lci nko
8 May 19
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
4:21pm
8-K
3vl1llgjsj
1 Apr 19
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial ofCPI-1205 at AACR Meeting
1:00pm
8-K
7fid93b3
21 Mar 19
Entry into a Material Definitive Agreement
6:40am
8-K
2oihain0np6y248
14 Mar 19
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
5:30pm
8-K/A
5qn753x
13 Mar 19
Departure of Directors or Certain Officers
4:18pm
8-K
r8k16
20 Feb 19
Announces Appointment to Board of
7:12am
8-K
8u61ryn3 mg
7 Jan 19
Regulation FD Disclosure
6:39am
8-K
rnemm4f2aj agueca
3 Jan 19
Regulation FD Disclosure
7:10am
8-K/A
541wgjvkpz0 wc9
17 Dec 18
Departure of Directors or Certain Officers
4:45pm
8-K
znq gvptst
10 Dec 18
Regulation FD Disclosure
4:52pm
8-K
hmeja
9 Nov 18
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
12:00am
8-K
ggti5z
1 Nov 18
Constellation Pharmaceuticals Receives FDA Fast Track Designation forCPI-0610 in Treatment of Myelofibrosis
7:12am
8-K
f84c7hn2at1ff6pt9 45
11 Oct 18
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study ofCPI-0610 in Myelofibrosis
12:00am
8-K
0f82wm
4 Sep 18
Constellation Pharmaceuticals Announces Appointments to Board of Directors
12:00am
8-K
rxr9qg9hoz1zmzt0
14 Aug 18
Constellation Pharmaceuticals Announces Second-Quarter andSix-Month 2018 Financial Results
4:29pm